Chinese biotech firm offers unproven iPS cell treatment

08/5/2008 | InformationWeek

China-based Beike Biotechnology is using a promising but untested therapy involving induced pluripotent stem cells to treat hundreds of patients -- many from Western countries -- suffering from diseases deemed incurable, such as cerebral palsy and muscular dystrophy. The company's technology, which uses a combination of umbilical-cord cells and stem cells extracted from patients, "may someday create the conditions for effective clinical treatments and industrial scale production of iPS cells," a U.S. researcher said.

View Full Article in:

InformationWeek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX